COMT inhibitors in Parkinson's disease: Can they prevent and/or reverse levodopa-induced motor complications?OLANOW, C. Warren; STOCCHI, Fabrizio.Neurology. 2004, Vol 62, Num 1, pp S72-S81, issn 0028-3878, SUP1Article

The pathogenesis of cell death in Parkinson's diseaseJENNER, Peter; OLANOW, C. Warren.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, S24-S36, SUP4Article

Continuous dopaminergic stimulation in early and advanced Parkinson's diseaseSTOCCHI, Fabrizio; OLANOW, C. Warren.Neurology. 2004, Vol 62, Num 1, pp S56-S63, issn 0028-3878, SUP1Article

Rationale for considering that propargylamines might be neuroprotective in Parkinson's diseaseOLANOW, C. Warren.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, S69-S79, SUP4Article

Levodopa-induced dyskinesiasOLANOW, C. Warren.Annals of neurology. 2000, Vol 47, Num 4, issn 0364-5134, 206 p., SUP1Serial Issue

Levodopa, COMT : Inhibition, and Continuous Dopaminergic StimulationOLANOW, C. Warren.Neurology. 2004, Vol 62, Num 1, issn 0028-3878, 83 p., SUP1Serial Issue

New approaches to neuroprotective therapy in Parkinson's diseaseOLANOW, C. Warren.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, 105 p., SUP4Serial Issue

Levodopa/Dopamine Replacement Strategies in Parkinson's Disease-Future DirectionsOLANOW, C. Warren.Movement disorders. 2008, Vol 23, issn 0885-3185, S613-S622, SUP3Article

The delayed-start study in Parkinson disease: Can't satisfy everyoneOLANOW, C. Warren; RASCOL, O.Neurology. 2010, Vol 74, Num 14, pp 1149-1150, issn 0028-3878, 2 p.Article

Selegiline and neuroprotection in Parkinson's diseaseOLANOW, C. Warren; RIEDERER, Peter.Neurology. 1996, Vol 47, Num 6, issn 0028-3878, 83 p., SUP3Serial Issue

Issues in neuroprotection clinical trials in Parkinson's diseaseKIEBURTZ, Karl.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, S50-S57, SUP4Article

The role of COMT inhibition in the treatment of Parkinson's diseasePOEWE, Werner.Neurology. 2004, Vol 62, Num 1, pp S31-S38, issn 0028-3878, SUP1Article

Avoidance of dyskinesia: Preclinical evidence for continuous dopaminergic stimulationJENNER, Peter.Neurology. 2004, Vol 62, Num 1, pp S47-S55, issn 0028-3878, SUP1Article

Parkinson's Disease, Proteins, and Prions: MilestonesOLANOW, C. Warren; MCNAUGHT, K.Movement disorders. 2011, Vol 26, Num 6, pp 1056-1071, issn 0885-3185, 16 p.Article

Defining Disease-Modifying Therapies for PD— A Road Map for Moving ForwardOLANOW, C. Warren; KIEBURTZ, Karl.Movement disorders. 2010, Vol 25, Num 12, pp 1774-1779, issn 0885-3185, 6 p.Article

The need for neuroprotective therapies in Parkinson's disease : A clinical perspectivePOEWE, Werner.Neurology. 2006, Vol 66, Num 10, issn 0028-3878, S2-S9, SUP4Article

Medical treatment of levodopa-induced dyskinesiasRASCOL, O.Annals of neurology. 2000, Vol 47, Num 4, pp S179-S188, issn 0364-5134, SUP1Article

Neuroprotection in Parkinson's disease: Clinical trials. DiscussionSTOCCHI, Fabrizio; OLANOW, C. Warren.Annals of neurology. 2003, Vol 53, pp S87-S99, issn 0364-5134, SUP3Article

Treatment of Levodopa-Induced Motor ComplicationsSTOCCHI, Fabrizio; TAGLIATI, Michele; OLANOW, C. Warren et al.Movement disorders. 2008, Vol 23, issn 0885-3185, S599-S612, SUP3Article

Drug Selection and Timing of Initiation of Treatment in Early Parkinson's DiseaseSCHAPIRA, Anthony H. V; OLANOW, C. Warren.Annals of neurology. 2008, Vol 64, Num 6, issn 0364-5134, S47-S55, SUPArticle

How Do You Treat Motor Complications in Parkinson's Disease : Medicine, Surgery, or Both?FAHN, Stanley.Annals of neurology. 2008, Vol 64, Num 6, issn 0364-5134, S56-S64, SUPArticle

New developments in levodopa therapyLEWITT, Peter A; NYHOLM, Dag.Neurology. 2004, Vol 62, Num 1, pp S9-S16, issn 0028-3878, SUP1Article

Physiology of hypokinetic and hyperkinetic movement disorders : Model for dyskinesiaVITEK, J. L; GIROUX, M.Annals of neurology. 2000, Vol 47, Num 4, pp S131-S140, issn 0364-5134, SUP1Article

An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelinesOLANOW, C. Warren; KOLLER, William C.Neurology. 1998, Vol 50, Num 3, issn 0028-3878, 60 p., SUP3Serial Issue

Is levodopa toxic ?FAHN, S.Neurology. 1996, Vol 47, Num 6, pp S184-S195, issn 0028-3878, SUP3Article